bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients Read more about bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma Read more about Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma
bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype Read more about bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype
bluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting Read more about bluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress Read more about bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress
Evercore ISI Biopharma Catalyst/Deep Dive Conference Read more about Evercore ISI Biopharma Catalyst/Deep Dive Conference
bluebird bio Announces ASH Abstract Conference Call on November 1st and Upcoming Investor Events in November Read more about bluebird bio Announces ASH Abstract Conference Call on November 1st and Upcoming Investor Events in November
bluebird bio to Present at Chardan Gene Therapy Conference Read more about bluebird bio to Present at Chardan Gene Therapy Conference
bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine Read more about bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine